Primordial germ cells (PGCs) are the precursors of reproductive gametes. They were first identified in the posterior region of embryos at the angle between the allantois and the wall of the yolk sac, and were shown to subsequently migrate into the forming gonadal ridges in early mouse and human embryos of both sexes (Eddy et al., 1981; Bendel-Stenzel et al., 1998) . PGCs will eventually differentiate into oogonia/oocytes in the female mammals. At birth, ovaries are filled with primordial follicles, which are differentiated from PGCs/oogonia (De Felici, 2010; De Felici and Barrios, 2013) .
The field of reproductive biology has maintained a long-standing dogma for decades, stating that a non-renewable pool of oocytecontaining follicles is established in female mammals at birth. This is perceived to be different from the renewable sperm pool in the testis of adult males, where spermatogonial stem cells can proliferate and produce sperm throughout the lifetime of the male (de Rooij and Kramer, 1968) . It is generally regarded that the germ cell generation in mammalian females ceases prior to birth, and that female mammals lose the capability to replenish or regenerate their oocyte reserve, resulting in a progressive and irreversible decrease in follicle numbers until the pool is exhausted at middle age (Faddy et al., 1992; Tilly and Telfer, 2009) . In 2004, this long-held concept was challenged by a study from Jonathan Tilly's group reporting the presence of ovarian germline cells, which had germ cell morphology, mitotic activity and the expression of MVH (mouse vasa homolog), a conserved germlinespecific marker. These cells were designated as putative female germline stem cells (FGSCs) and identified in or proximal to the surface epithelium of juvenile and adult mouse ovaries ( Johnson et al., 2004) . Since then, the existence of FGSCs in the post-natal ovary has been much debated. In 2004, Roger Gosden wrote a commentary 'Germline stem cells in the post-natal ovary: is the ovary more like a testis?' (Gosden, 2004) and in the following year, Telfer et al. responded with an article 'On regenerating the ovary and generating controversy' (Telfer et al., 2005) . The subsequent experiments from the Tilly group indicated a possible extra-ovarian origin of FGSCs in the adult mouse from circulating bone marrow or peripheral blood cells ( Johnson et al., 2005) . Gradually there have been more studies in different species from different laboratories to add to the above findings. In 2006, Eggan et al. demonstrated that the circulating germ cells from bone marrow or blood cells failed to generate oocytes in adult mice after induction (Eggan et al., 2006) . However, in 2009, Ji Wu and colleagues published a study showing that mouse offspring could be produced using an FGSC stem cell line derived from neonatal or adult mouse ovaries (Zou et al., 2009) . This was the first publication reporting that the proliferative FGSCs can be purified from the post-natal ovary by using immunomagnetic sorting with antibodies against MVH. FGSC culture can be maintained in vitro for months; furthermore, these FGSCs can restore oogenesis after transplantation into the ovaries of chemotherapy-sterilized recipients and produce fertile offspring. Although these findings do not confirm that oogenesis can occur in adult humans under physiological conditions, they provide strong evidence for the existence of FGSCs in post-natal mouse ovaries, and have attracted a substantial amount of interest from scientists in the field of reproductive biology (Normile, 2009; Tilly and Telfer, 2009) . Recently, other groups have explored how to proliferate and differentiate FGSCs from the post-natal mouse ovaries (Pacchiarotti et al., 2010; Hu et al., 2012) . All these findings from murine models have stimulated interest in using FGSCs for future clinical application, and several studies of FSGCs in human ovaries have emerged (Liu et al., 2007; Virant-Klun et al., 2008 , 2009 Byskov et al., 2011) . Some of them claimed no presence of FGSCs in post-natal human ovaries. However, in 2012, White et al. from the Tilly group revived interest for clinical FGSC application by their observation that mitotically active germ cells purified from ovaries of reproductive-age women were able to form oocytes (White et al., 2012) . The morphology of the FGSCs from this study is different from that shown by Virant-Klun et al. (2008 , 2009 . All these experimental results from post-natal ovaries in human have raised the prospect of using FGSCs to combat aging and female-related reproductive diseases. However, in 2012, a study from Kui Liu's group provided contrary evidence that no mitotically active female germline progenitors exist in post-natal mouse ovaries (Zhang et al., 2012) . In this study, unlike most of the above studies, which used immunomagnetic or FACS sorting with Vasa or other germ cell markers to isolate putative FGSCs (Zou et For Permissions, please email: journals.permissions@oup.com experiments, they showed that the Ddx4-expressing cells from postnatal mouse ovaries did not enter mitosis, nor did they contribute to oocytes during de novo folliculogenesis. Subsequently, several emerging studies in mouse and monkey supported the negative findings of the Liu group (Lei and Spradling, 2013; Yuan et al., 2013) . The debate over the existence of mitotically active FGSCs or oogonial stem cells during post-natal life in mammals continues (Woods et al., 2013; Zhang et al., 2013) , and new research in this field is needed.
In the March issue of Molecular Human Reproduction, Zhou et al. reported an interesting study demonstrating that an FGSC stem cell line could be established from post-natal rat ovaries, and fat-1 transgenic rats were generated using these cultured FGSCs (Zhou et al., 2014) . Zou et al. (2009) are from the same group who previously published generating mouse offspring using the FGSC from the neonatal mice ovaries, using a similar protocol. Zhou et al. (2014) first located the FGSCs in the cortical surface of ovaries in 4-5-week-old rats. The FGSCs were positive for Ddx4 (a rat orthologue of MVH) and Fragilis (Ifitm3, a marker of germ cells, especially early germ cells). Using immunomagnetic sorting for Fragilis, by which they could purify FGSCs with higher efficiency than MVH in their earlier study (Zou et al., 2011) , the authors could isolate FGSCs from 5-day-old rats. They cultured these cells on inactivated feeder cells and established the FGSC cell line with similar characteristics to the FGSCs found in mice. After 1 year of in vitro culturing, the FGSC cell line still maintains consistent characteristics and the capability to proliferate and differentiate, including the in vitro and in vivo differentiation into oocytes. Furthermore, to confirm the capability of oogenesis in vivo, cultured FGSCs were transduced with GFP (green fluorescent protein) vectors and transplanted into ovaries of the chemotherapy-sterilized rat recipients. Two months after transplantation, the GFP-positive oocytes were found in the ovaries of FGSC transplanted group. Moreover, the fertile rat offspring carrying GFP could be produced after the recipient rats were mated with wild-type rats, which suggested that FGSCs could restore the fertility of sterilized recipients by regenerating oocytes. The transgene could also be germ line transmitted into F2 generations. Using a similar method, the fat-1 transgenic rat has been successfully generated using FGSCs, with transgene fat-1 functionally active in vivo. The efficiency of gene transfer was around 28% and it took 2 months to produce transgenic rats (Zhou et al., 2014) .
In the first place, by using FGSCs, Zhao et al. paper provides an important tool to generate transgenic rats in a relatively easy and quick way compared with using embryonic stem cells. In this paper, for the first time, the authors produced functional fat-1 transgenic rats. The rat is a much better animal model for humans than mice in biomedical research. This is a significant advance. Secondly, this study provides further strong evidence to support the existence of FGSCs in post-natal ovaries, although open questions about these rat FGSCs remain to be elucidated: Where do these rat FGSCs come from? Are they different from the stem cells in the ovarian surface epithelium? Are they inner cells of the ovary that acquired 'stemness' during in vitro culture? If 'rescued' do FGSCs bear some negative features inappropriate for normal oogenesis? Do they form teratomas? Can these FGSCs still be found in ovaries of aged females? Many facts remain elusive, such as whether oogenesis occurs in adult females under physiological conditions, or why the oocyte pool in the post-natal ovary is non-renewable if ovarian FGSCs exist, and what are the reasons for the discrepant results obtained by different groups using different strategies. As some of the latest commentaries stated, we believe that continuing debate and additional research will eventually provide solutions to combat the infertility problems associated with aging (Woods et al., 2013; Zhang et al., 2013) . Although the isolation of rat FGSCs cannot be directly translated to the human situation, nevertheless, without doubt, the generation of transgenic rats using the FGSCs from the post-natal ovary by Zhou et al. will have significant implications in biomedical research.
